Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT

Allogeneic hematopoietic cell transplantation (allo-HCT) remains a treatment option for patients with chronic myeloid leukemia (CML) who fail to respond to tyrosine kinase inhibitors (TKIs). While imatinib seems to have no adverse impact on outcomes after transplant, little is known on the effects o...

Descripción completa

Detalles Bibliográficos
Autores principales: Masouridi-Levrat, Stavroula, Olavarria, Eduardo, Iacobelli, Simona, Aljurf, Mahmoud, Morozova, Elena, Niittyvuopio, Riitta, Sengeloev, Henrik, Reményi, Peter, Helbig, Grzegorz, Browne, Paul, Ganser, Arnold, Nagler, Arnon, Snowden, John A., Robin, Marie, Passweg, Jakob, Van Gorkom, Gwendolyn, Wallet, Hélène Labussière, Hoek, Jennifer, Blok, Henric-Jan, De Witte, Theo, Kroeger, Nicolaus, Hayden, Patrick, Chalandon, Yves, Agha, Ibrahim Yakoub
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732279/
https://www.ncbi.nlm.nih.gov/pubmed/34599284
http://dx.doi.org/10.1038/s41409-021-01472-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732279/
https://www.ncbi.nlm.nih.gov/pubmed/34599284
http://dx.doi.org/10.1038/s41409-021-01472-x

Ejemplares similares